- Novartis Q2 2026: approvals for Rhapsido (EU, Japan) and Itvisma (EU); Kisqali six‑year follow‑up and FDA pediatric exclusivity; Del‑zota BLA submitted; Del‑brax positive Phase I/II biomarkers.
- Novartis (NOVN) Q quarter: Entresto sales fell 50% to $1.18B as US generics hit. European patent exclusivity starts in November; analysts expect slower decline later in year.
- Novartis (NOVN) Q2 2026: sales and core operating profit beat estimates; generic erosion hit results more than expected, affecting near-term revenue and margins.
- Novartis AG (NOVN) reaffirmed 2026 guidance: low-single-digit net sales growth and low-single-digit core operating income decline; FX translation expected to add ~1 percentage point to both metrics.
TradingView
Key facts: Novartis Q2 approvals/pipeline; generics dent; Entresto -50%
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- SIX:NOVN
- Language
- English
Novartis Q2 2026: approvals for Rhapsido (EU, Japan) and Itvisma (EU); Kisqali six‑year follow‑up and FDA pediatric exclusivity; Del‑zota BLA submitted; Del‑brax positive Phase I/I